Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2

Interventions

Carboplatin 351pembrolizumab 327Pemetrexed 249Cisplatin 221Paclitaxel 149Nivolumab 139durvalumab 134Docetaxel 112osimertinib 111atezolizumab 107Specimen Handling 91Radiotherapy 89Drug Therapy 87Magnetic Resonance Spectroscopy 78Etoposide 78Radiosurgery 74Gemcitabine 72Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 53cemiplimab 47tislelizumab 46Blood Specimen Collection 43Cetuximab 35Taxes 34Injections 33Biopsy 33Standard of Care 32Platinum 32Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
necitumumab × Thoracic × 1 year × Clear all
NCT02496663 2026-05-13

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

National Cancer Institute (NCI)

Phase 1 Active not recruiting
138 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04285671 2026-03-10

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Active not recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00981058 2025-06-18

SQUIRE

Eli Lilly and Company

Phase 3 Completed
1,093 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡